Paris Regional Medical Center will now be providing monoclonal anti-body treatments for people who have COVID but are not ill enough to require hospitalization. Those processes and procedures include both bamlanivimab/casirivimab and imdevimab. Prospective patients must have a confirmed COVID diagnosis, be over age 65, have underlying health conditions, and be stable enough not to require hospitalization. The treatment involves a prescription from the patient’s doctor.